155 related articles for article (PubMed ID: 26982101)
1. Probing binding mechanism of interleukin-6 and olokizumab: in silico design of potential lead antibodies for autoimmune and inflammatory diseases.
Verma R; Yadav M; Pradhan D; Bhuyan R; Aggarwal S; Nayek A; Jain AK
J Recept Signal Transduct Res; 2016 Dec; 36(6):601-616. PubMed ID: 26982101
[TBL] [Abstract][Full Text] [Related]
2. Analysis of interleukin 23 and 7G10 interactions for computational design of lead antibodies against immune-mediated inflammatory diseases.
Saba Khan N; Verma R; Pradhan D; Nayek A; Bhuyan R; Kumar Sahu T; Kumar Jain A
J Recept Signal Transduct Res; 2018 Aug; 38(4):327-334. PubMed ID: 30481093
[TBL] [Abstract][Full Text] [Related]
3. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.
Shaw S; Bourne T; Meier C; Carrington B; Gelinas R; Henry A; Popplewell A; Adams R; Baker T; Rapecki S; Marshall D; Moore A; Neale H; Lawson A
MAbs; 2014; 6(3):774-82. PubMed ID: 24670876
[TBL] [Abstract][Full Text] [Related]
4. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
Tanaka T; Narazaki M; Ogata A; Kishimoto T
Semin Immunol; 2014 Feb; 26(1):88-96. PubMed ID: 24594001
[TBL] [Abstract][Full Text] [Related]
5. Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers.
Ho LJ; Luo SF; Lai JH
Biochem Pharmacol; 2015 Sep; 97(1):16-26. PubMed ID: 26080005
[TBL] [Abstract][Full Text] [Related]
6. [Anti-IL-6 : new therapeutic trends].
Candil M; Zufferey P
Rev Med Suisse; 2017 Jan; 13(544-545):105-109. PubMed ID: 28703549
[TBL] [Abstract][Full Text] [Related]
7. IsAb: a computational protocol for antibody design.
Liang T; Chen H; Yuan J; Jiang C; Hao Y; Wang Y; Feng Z; Xie XQ
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33876197
[TBL] [Abstract][Full Text] [Related]
8. One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β.
Blech M; Peter D; Fischer P; Bauer MM; Hafner M; Zeeb M; Nar H
J Mol Biol; 2013 Jan; 425(1):94-111. PubMed ID: 23041424
[TBL] [Abstract][Full Text] [Related]
9. [Humanized anti-human IL-6 receptor antibody, tocilizumab].
Nishimoto N
Nihon Rinsho; 2007 Jul; 65(7):1218-25. PubMed ID: 17642235
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapeutic implication of IL-6 blockade.
Tanaka T; Kishimoto T
Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
[TBL] [Abstract][Full Text] [Related]
11. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
12. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.
Tanaka T; Narazaki M; Kishimoto T
FEBS Lett; 2011 Dec; 585(23):3699-709. PubMed ID: 21419125
[TBL] [Abstract][Full Text] [Related]
13. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.
Tanaka T; Kishimoto T
Int J Biol Sci; 2012; 8(9):1227-36. PubMed ID: 23136551
[TBL] [Abstract][Full Text] [Related]
14. In silico design of small peptides antagonist against leptin receptor for the treatment of obesity and its associated immune-mediated diseases.
Munikumar M; Krishna VS; Reddy VS; Rajeswari B; Sriram D; Rao MV
J Mol Graph Model; 2018 Jun; 82():20-36. PubMed ID: 29649778
[TBL] [Abstract][Full Text] [Related]
15. Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody.
Mihara M; Ohsugi Y; Kishimoto T
Biofactors; 2009; 35(1):47-51. PubMed ID: 19319845
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic targeting of the interleukin-6 receptor.
Tanaka T; Narazaki M; Kishimoto T
Annu Rev Pharmacol Toxicol; 2012; 52():199-219. PubMed ID: 21910626
[TBL] [Abstract][Full Text] [Related]
17. Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region.
Sato K; Ohtomo T; Hirata Y; Saito H; Matsuura T; Akimoto T; Akamatsu K; Koishihara Y; Ohsugi Y; Tsuchiya M
Hum Antibodies Hybridomas; 1996; 7(4):175-83. PubMed ID: 9140729
[TBL] [Abstract][Full Text] [Related]
18. Targeting Olokizumab-Interleukin 6 interaction interface to discover novel IL-6 inhibitors.
Tran QH; Cao HN; Nguyen DN; Tran TT; Le MT; Nguyen QT; Tran VT; Tran VH; Thai KM
J Biomol Struct Dyn; 2023; 41(23):14003-14015. PubMed ID: 36995131
[TBL] [Abstract][Full Text] [Related]
19. [New therapeutic strategy for autoimmune and chronic inflammatory disease based on clinical results using IL-6 blocking therapy with a humanized anti-IL-6 receptor antibody].
Yoshizaki K
Yakugaku Zasshi; 2009 Jun; 129(6):667-74. PubMed ID: 19483409
[TBL] [Abstract][Full Text] [Related]
20. Computer-Aided Antibody Design: An Overview.
Choong YS; Lee YV; Soong JX; Law CT; Lim YY
Adv Exp Med Biol; 2017; 1053():221-243. PubMed ID: 29549642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
